Loading...

CEL-SCI

DB:LSRM
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LSRM
DB
$221M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The last earnings update was 70 days ago. More info.


Add to Portfolio Compare Print
  • CEL-SCI has significant price volatility in the past 3 months.
LSRM Share Price and Events
7 Day Returns
18.2%
DB:LSRM
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
279%
DB:LSRM
-5.6%
DE Biotechs
-4.5%
DE Market
LSRM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CEL-SCI (LSRM) 18.2% 126.2% 146.9% 279% -51.5% -71.3%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • LSRM outperformed the Biotechs industry which returned -5.6% over the past year.
  • LSRM outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
LSRM
Industry
5yr Volatility vs Market
Related Companies

LSRM Value

 Is CEL-SCI undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CEL-SCI. This is due to cash flow or dividend data being unavailable. The share price is €5.95.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CEL-SCI's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CEL-SCI's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:LSRM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.16
AMEX:CVM Share Price ** AMEX (2019-04-25) in USD $6.96
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CEL-SCI.

DB:LSRM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:CVM Share Price ÷ EPS (both in USD)

= 6.96 ÷ -1.16

-6.01x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CEL-SCI is loss making, we can't compare its value to the Europe Biotechs industry average.
  • CEL-SCI is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CEL-SCI's expected growth come at a high price?
Raw Data
DB:LSRM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.01x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
34.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CEL-SCI, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CEL-SCI's assets?
Raw Data
DB:LSRM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.10
AMEX:CVM Share Price * AMEX (2019-04-25) in USD $6.96
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:LSRM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:CVM Share Price ÷ Book Value per Share (both in USD)

= 6.96 ÷ 0.10

71.57x

* Primary Listing of CEL-SCI.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CEL-SCI is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CEL-SCI's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CEL-SCI has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LSRM Future Performance

 How is CEL-SCI expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CEL-SCI expected to grow at an attractive rate?
  • Unable to compare CEL-SCI's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare CEL-SCI's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • CEL-SCI's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:LSRM Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:LSRM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 34.5%
DB:LSRM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -13.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:LSRM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:LSRM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-09-30 0 -13 1
2019-09-30 0 -15 1
DB:LSRM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -15 -24
2018-09-30 0 -13 -32
2018-06-30 0 -13 -22
2018-03-31 0 -13 -20
2017-12-31 0 -12 -24
2017-09-30 -14 -14
2017-06-30 0 -17 -10
2017-03-31 0 -20 -10
2016-12-31 0 -21 -10
2016-09-30 0 -23 -12
2016-06-30 0 -22 -20
2016-03-31 0 -22 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CEL-SCI is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • CEL-SCI's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:LSRM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from CEL-SCI Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LSRM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-09-30 -0.27 -0.27 -0.27 1.00
2019-09-30 -0.42 -0.42 -0.42 1.00
DB:LSRM Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.16
2018-09-30 -1.87
2018-06-30 -1.65
2018-03-31 -1.81
2017-12-31 -2.59
2017-09-30 -1.83
2017-06-30 -1.55
2017-03-31 -1.67
2016-12-31 -1.96
2016-09-30 -2.37
2016-06-30 -4.50
2016-03-31 -5.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CEL-SCI will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CEL-SCI's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CEL-SCI has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LSRM Past Performance

  How has CEL-SCI performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CEL-SCI's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CEL-SCI does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare CEL-SCI's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CEL-SCI's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
CEL-SCI's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CEL-SCI Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LSRM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.51 -24.42 7.18
2018-09-30 0.48 -31.85 7.85
2018-06-30 0.28 -21.97 7.28
2018-03-31 0.19 -20.42 7.12
2017-12-31 0.08 -24.14 7.09
2017-09-30 -14.43 5.80
2017-06-30 0.15 -10.50 7.95
2017-03-31 0.27 -9.90 8.03
2016-12-31 0.28 -10.32 7.26
2016-09-30 0.29 -11.51 7.59
2016-06-30 0.12 -20.25 6.86
2016-03-31 0.38 -20.81 8.05
2015-12-31 0.54 -24.51 10.37
2015-09-30 0.66 -34.69 13.86
2015-06-30 0.79 -32.05 15.13
2015-03-31 0.42 -30.07 14.66
2014-12-31 0.29 -30.88 13.85
2014-09-30 0.26 -28.47 10.67
2014-06-30 0.21 -22.96 7.99
2014-03-31 0.31 -25.02 7.37 -5.44
2013-12-31 0.26 -12.37 6.93
2013-09-30 0.16 -9.23 6.96
2013-06-30 0.25 -10.10 6.83
2013-03-31 0.17 -6.43 6.72 0.39
2012-12-31 0.26 -15.80 6.70 -2.46
2012-09-30 0.25 -17.65 6.55
2012-06-30 0.32 -17.40 6.43 2.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CEL-SCI has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CEL-SCI has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CEL-SCI improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CEL-SCI's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CEL-SCI has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LSRM Health

 How is CEL-SCI's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CEL-SCI's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CEL-SCI is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CEL-SCI's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of CEL-SCI's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CEL-SCI Company Filings, last reported 3 months ago.

DB:LSRM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 2.71 13.41 6.68
2018-09-30 0.00 13.38 10.31
2018-06-30 -1.25 13.34 2.35
2018-03-31 -3.06 14.47 3.06
2017-12-31 -4.83 14.13 2.14
2017-09-30 -3.34 14.21 2.37
2017-06-30 -5.08 13.49 1.23
2017-03-31 -2.83 13.11 1.53
2016-12-31 4.69 13.06 2.39
2016-09-30 -0.68 13.01 2.92
2016-06-30 -3.77 0.00 5.22
2016-03-31 -2.94 0.00 6.05
2015-12-31 3.53 1.11 10.42
2015-09-30 -4.76 13.89 5.73
2015-06-30 3.93 1.28 11.23
2015-03-31 0.34 1.12 2.61
2014-12-31 11.84 1.12 9.46
2014-09-30 10.44 1.12 8.51
2014-06-30 15.04 1.12 14.29
2014-03-31 7.36 1.13 10.61
2013-12-31 15.11 1.14 13.49
2013-09-30 6.70 1.13 0.04
2013-06-30 7.80 1.14 3.48
2013-03-31 11.55 1.14 6.99
2012-12-31 11.62 1.14 10.74
2012-09-30 7.03 1.10 3.94
2012-06-30 9.01 1.10 7.22
  • CEL-SCI's level of debt (495.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (7.6% vs 495.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CEL-SCI has less than a year of cash runway based on current free cash flow.
  • CEL-SCI has less than a year of cash runway if free cash flow continues to reduce at historical rates of -23.8% each year.
X
Financial health checks
We assess CEL-SCI's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CEL-SCI has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LSRM Dividends

 What is CEL-SCI's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CEL-SCI dividends.
If you bought €2,000 of CEL-SCI shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CEL-SCI's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CEL-SCI's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:LSRM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:LSRM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-09-30
2019-09-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CEL-SCI has not reported any payouts.
  • Unable to verify if CEL-SCI's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CEL-SCI's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CEL-SCI has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CEL-SCI's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CEL-SCI afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CEL-SCI has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LSRM Management

 What is the CEO of CEL-SCI's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Geert Kersten
COMPENSATION $4,753,929
AGE 59
TENURE AS CEO 24.2 years
CEO Bio

Mr. Geert R. Kersten, Esq., has been the Chief Executive Officer at CEL-SCI Corporation since February 1995 and serves as its Principal Financial and Accounting Officer. Mr. Kersten serves as the Chief Executive Officer and Treasurer of CEL-SCI Corporation since February 1995 and 1989 respectively. He has been involved in the pioneering field of cancer immunotherapy for over two decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI's Multikine product could potentially change the way cancer is treated. Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He served as a Director of Corporate and Investment Relations for CEL-SCI from February 1987 to October 1987. He served as Vice President of Operations at CEL-SCI Corp. since October 1987. Mr. Kersten served as Chief Operating Officer of CEL-SCI Corp. Mr. Kersten worked as a financial analyst with Source Capital, Ltd. Mr. Kersten has been a Director of CEL-SCI Corporation since December 1988. Mr. Kersten attended George Washington University in Washington, D.C., where he earned a B.A. in Accounting and an MBA with emphasis on International Finance. He also attended law school at American University in Washington, D.C. where he received a Juris Doctor degree. He Graduated from Millfield School in England.

CEO Compensation
  • Geert's compensation has increased whilst company is loss making.
  • Geert's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CEL-SCI management team in years:

23.3
Average Tenure
67
Average Age
  • The average tenure for the CEL-SCI management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Geert Kersten

TITLE
CEO, Principal Accounting & Financial Officer
COMPENSATION
$5M
AGE
59
TENURE
24.2 yrs

Patricia Prichep

TITLE
Senior VP of Operations & Corporate Secretary
COMPENSATION
$611K
AGE
67
TENURE
25.1 yrs

Eyal Talor

TITLE
Chief Scientific Officer
COMPENSATION
$962K
AGE
62
TENURE
9.5 yrs

Daniel Zimmerman

TITLE
Senior Vice President of Research & Cellular Immunology
COMPENSATION
$537K
AGE
77
TENURE
23.3 yrs

John Cipriano

TITLE
Senior Vice President of Regulatory Affairs
COMPENSATION
$517K
AGE
76
TENURE
15.1 yrs
Board of Directors Tenure

Average tenure and age of the CEL-SCI board of directors in years:

10.3
Average Tenure
63.5
Average Age
  • The average tenure for the CEL-SCI board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Geert Kersten

TITLE
CEO, Principal Accounting & Financial Officer
COMPENSATION
$5M
AGE
59
TENURE
30.3 yrs

Peter Young

TITLE
Independent Director
COMPENSATION
$203K
AGE
73
TENURE
16.7 yrs

Bruno Baillavoine

TITLE
Independent Director
COMPENSATION
$203K
AGE
66
TENURE
3.8 yrs

Bob Watson

TITLE
Independent Director
COMPENSATION
$198K
AGE
61
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by CEL-SCI insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Apr 19 Buy Peter Young Individual 05. Apr 19 05. Apr 19 2,000 €4.64 €9,274
19. Feb 19 Buy Peter Young Individual 14. Feb 19 14. Feb 19 1,000 €2.50 €2,501
02. Jan 19 Sell Daniel Zimmerman Individual 31. Dec 18 31. Dec 18 -2,474 €2.56 €-6,331
03. May 18 Buy Peter Young Individual 01. May 18 01. May 18 2,000 €1.78 €3,567
01. May 18 Buy Peter Young Individual 27. Apr 18 27. Apr 18 4,000 €1.97 €7,881
X
Management checks
We assess CEL-SCI's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CEL-SCI has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LSRM News

Simply Wall St News

LSRM Company Info

Description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company’s lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Details
Name: CEL-SCI Corporation
LSRM
Exchange: DB
Founded: 1983
$198,704,459
33,033,395
Website: http://cel-sci.com
Address: CEL-SCI Corporation
8229 Boone Boulevard,
Suite 802,
Vienna,
Virginia, 22182,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX CVM Common Stock NYSE MKT LLC US USD 08. Dec 1983
DB LSRM Common Stock Deutsche Boerse AG DE EUR 08. Dec 1983
Number of employees
Current staff
Staff numbers
0
CEL-SCI employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 21:43
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/01/31
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.